Abstract #4080
Can Diffusion-Weighted Imaging Detect Antihormonal Resistance in Patients with Prostate Cancer Bone Metastases?
Carolin Reischauer 1,2 , Johannes M. Froehlich 1 , Dow-Mu Koh 3 , Ren Patzwahl 4 , Christoph A. Binkert 4 , Sebastian Kos 1 , and Andreas Gutzeit 1,5
1
Institute of Radiology and Nuclear Medicine,
Clinical Research Unit, Hirslanden Klinik St. Anna,
Lucerne, Switzerland,
2
Institute
for Biomedical Engineering, ETH and University Zurich,
Zurich, Switzerland,
3
Department
of Radiology, Royal Marsden Hospital, Sutton, United
Kingdom,
4
Department
of Radiology, Cantonal Hospital Winterthur, Winterthur,
Switzerland,
5
Department
of Radiology, Paracelsus Medical University, Salzburg,
Austria
Patients suffering from prostate cancer-related bone
metastases initially respond well to antihormonal
treatment. However, after a period of 2-3 years
resistance is usually observed. The present work
investigates whether diffusion-weighted imaging permits
monitoring this process. It has been previously shown
that increased apparent diffusion coefficients (ADCs)
are observed at 1 month after commencement of therapy in
responders to androgen deprivation. Using ADCs and
functional diffusion maps, the present work shows that
this initial increase is followed by decreasing ADCs
with onset of antihormonal resistance.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
